Clinical trials / Alcohol use disorder
Recruiting psychedelic and ketamine trials for alcohol use disorder
12 trials registered on ClinicalTrials.gov were recruiting on 26 Oct 2026, 5 of them at sites in the United States (4 states). By substance: Ketamine / esketamine 5, Psilocybin 5, MDMA 1, DMT / ayahuasca 1, LSD 1.
What the published research shows so far: Psilocybin, LSD and ketamine for alcohol use disorder
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Trials with US sites
Phase 2/3MDMANCT07118839
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (MAP VETS)
- Conditions:
- Post Traumatic Stress Disorder; Alcohol Use Disorder
- Sponsor:
- VA Office of Research and Development
- Who:
- ages 18 Years and over, 80 participants planned
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT, West Haven, Connecticut
- Providence VA Medical Center, Providence, RI, Providence, Rhode Island
Phase 2Ketamine / esketamineNCT02122562
Ketamine Alcohol (in Treatment-Resistant Depression)
- Conditions:
- Magnetic Resonance Imaging; Major Depression; Alcoholism
- Sponsor:
- Mark Niciu
- Who:
- ages 18 Years to 55 Years, 60 participants planned
- University of Iowa Health Care, Iowa City, Iowa
Phase 1DMT / ayahuascaNCT06070649
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
- Conditions:
- Alcohol Use Disorder (AUD); Alcohol-Related Disorders; Alcohol Use
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 65 Years, 63 participants planned
- Connecticut Mental Health Center, New Haven, Connecticut
Phase 2PsilocybinNCT06349083
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
- Conditions:
- Alcohol Use Disorder
- Sponsor:
- NYU Langone Health
- Who:
- ages 18 Years to 65 Years, 200 participants planned
- NYU Langone Health, New York, New York
Phase 2Psilocybin, Ketamine / esketamineNCT06405607
Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial (Psi or Ket)
- Conditions:
- Alcohol Use Disorder; Alcohol Dependence; Alcohol Abuse
- Sponsor:
- University of Iowa
- Who:
- ages 21 Years to 65 Years, 80 participants planned
- University of Iowa Health Care, Iowa City, Iowa
Trials outside the United States
Phase 2LSDNCT05474989
LSD Treatment for Persons With Alcohol Use Disorder (LYTA)
- Conditions:
- Alcohol Use Disorder (AUD)
- Sponsor:
- Felix Mueller
- Who:
- ages 25 Years and over, 128 participants planned
- Where:
- Switzerland
Phase 2PsilocybinNCT05995769
Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder (PAP-AUD)
- Conditions:
- Alcohol Use Disorder; Alcoholism
- Sponsor:
- University of Calgary
- Who:
- ages 22 Years to 65 Years, 128 participants planned
- Where:
- Canada
Phase 1/2Ketamine / esketamineNCT06090422
Ketamine for Combined Depression and Alcohol Use Disorder (KeDA)
- Conditions:
- Depression; Alcohol Use Disorder
- Sponsor:
- University Hospital of North Norway
- Who:
- ages 18 Years to 65 Years, 34 participants planned
- Where:
- Norway
Phase not statedKetamine / esketamineNCT06620276
ACT_for Alcohol Use Disorder and Depression
- Conditions:
- Depression - Major Depressive Disorder; Alcohol Use Disorder
- Sponsor:
- Centre hospitalier de l'Université de Montréal (CHUM)
- Who:
- ages 18 Years to 70 Years, 30 participants planned
- Where:
- Canada
Phase 2Ketamine / esketamineNCT06969937
Ketamine and Neurofeedback as Combined Therapeutic Interventions to Target Glutamatergic Neurotransmission in Alcohol Use Disorder (Nektar)
- Conditions:
- Alcohol Abuse/Dependence; Alcohol Use Disorder (AUD); Alcoholism
- Sponsor:
- Dr. med. Marcus Herdener
- Who:
- ages 18 Years to 65 Years, 75 participants planned
- Where:
- Switzerland
Phase 2PsilocybinNCT07405606
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
- Conditions:
- Major Depressive Disorder (MDD); Alcohol Use Disorder (AUD)
- Sponsor:
- Centre for Addiction and Mental Health
- Who:
- ages 18 Years to 65 Years, 30 participants planned
- Where:
- Canada
Phase 3PsilocybinNCT07638553
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms (ERPPAD)
- Conditions:
- Alcohol Use Disorder; Depressive Sympotoms; Psilocybin
- Sponsor:
- Centre Hospitalier Universitaire de Nīmes
- Who:
- ages 18 Years and over, 172 participants planned
- Where:
- France